Primary CNS lymphoma treated with radiotherapy in Japan: a survey of patients treated in 2005–2009 and a comparison with those treated in 1985–2004

Yuta Shibamoto, Minako Sumi, Shunsuke Onodera, Haruo Matsushita, Chikao Sugie, Yukihisa Tamaki, Hiroshi Onishi, Eisuke Abe, Masahiko Koizumi, Daisuke Miyawaki, Seiji Kubota, Etsuyo Ogo, Takuma Nomiya, Mitsuhiro Takemoto, Hideyuki Harada, Ippei Takahashi, Yoshio Ohmori, Naoya Ishibashi, Sunao Tokumaru, Kazunori Suzuki

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Conclusions: Although patient backgrounds differed among the study periods, recent trends were a high patient age, better PS, avoidance of extensive tumor resection, more frequent use of chemotherapy, and improved survival. The recent improvement in survival may be due to improvements in second-line treatment and supportive care.

Background: The aim of our study was to analyze changes over time in the characteristics, treatment, and outcome of patients with primary central nervous system lymphoma (PCNSL).

Methods: Data on 315 patients with histologically proven PCNSL undergoing radiotherapy between 2005 and 2009 were collected from 20 Japanese institutions using a questionnaire. These data were then compared with data on 273 patients treated during the period 1995–2004 and those on 466 patients treated during the period 1985–1994.

Results: In terms of patient and tumor characteristics, we found a significant increase in mean patient age in the 2005–2009 period compared to the 1985–2004 period (63 vs. 58–59 years, respectively) and in the percentage of patients with better performance status (PS) during the 2005–2009 period compared with the 1995–2004 period (World Health Organization PS 0–2: 73 vs. 65 %, respectively). Regarding treatment, relative to the 1995–2004 period, significant changes in the 2005–2009 period were (1) decreased rate of attempting tumor resection (23 vs. 44 %); (2) increased use of chemotherapy (78 vs. 68 %), and (3) increased use of methotrexate (MTX)-containing regimens (84 vs. 53 %). The 5-year overall survival rates were 15.3, 30.1, and 36.5 % for patients seen during the 1985–1994, 1995–2004, and 2005–2009 periods, respectively, but relapse-free survival did not improve between the 1995–2004 and 2005–2009 periods (26.7  vs. 25.7 % at 5 years, respectively). Patients receiving MTX-containing chemotherapy had 5-year survival rates of 19, 50, and 44 % during these three periods, respectively.

Original languageEnglish
Pages (from-to)963-971
Number of pages9
JournalInternational Journal of Clinical Oncology
Issue number5
Publication statusPublished - 2014 Oct 16


  • Chemotherapy
  • Lymphoma
  • Primary CNS lymphoma
  • Radiotherapy
  • Soluble interleukin-2 receptor

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology


Dive into the research topics of 'Primary CNS lymphoma treated with radiotherapy in Japan: a survey of patients treated in 2005–2009 and a comparison with those treated in 1985–2004'. Together they form a unique fingerprint.

Cite this